Objectives: To determine in vitro susceptibilities of a large series of speciated coagulasenegative staphylococci (CNS) against three new antibiotics, linezolid, quinupristin/dalfopristin and telithromycin. Methods: Susceptibilities to three new antibiotics and oxacillin, vancomycin, clindamycin and erythromycin were determined by the agar dilution method, as described by the NCCLS. Results: Resistance to linezolid was not observed in any isolates, although MIC 90 values varied between species. Fifteen of 658 (2.3%) isolates were resistant to quinupristin/dalfopristin, but <1% of the clinically most important isolates of Staphylococcus epidermidis, Staphylococcus haemolyticus and Staphylococcus hominis demonstrated resistance to this agent. Susceptibility to clindamycin correlated with susceptibility to quinupristin/dalfopristin; however, resistance to clindamycin did not predict quinupristin/dalfopristin resistance. Telithromycin was the least active of the new agents tested, showing activity similar to that of clindamycin. Susceptibility and resistance to clindamycin were predictive of susceptibility and resistance to telithromycin. Conclusion: Clindamycin susceptibility can be used as a surrogate marker for susceptibility to quinupristin/dalfopristin and telithromycin. Quinupristin/dalfopristin and linezolid show good activity against both mecA-positive and -negative CNS.
Introduction
Over the last decades, the incidence of nosocomially acquired Gram-positive infections has increased, and coagulasenegative staphylococci (CNS) are now a major cause of hospital-acquired bloodstream infections. 1, 2 They are the most common cause of infections associated with the presence of intravascular catheters, cerebrospinal fluid shunts, prosthetic valves, orthopaedic devices, pacemakers, dialysis catheters and vascular grafts. Typically between 50% and 80% of CNS, depending on the species, are mecA positive. 2, 3 Antimicrobial resistance in these organisms has complicated treatment of infections and vancomycin has become the first line agent for these infections. 4, 5 The purpose of this study was to determine the in vitro activity of three new antimicrobials, linezolid, quinupristin/ dalfopristin and telithromycin, against a collection of speciated CNS. For the purpose of comparison, the MICs of clindamycin, erythromycin, oxacillin and vancomycin were determined.
Materials and methods
A total of 658 non-duplicate clinical isolates of CNS were collected from patients at the University and Victoria Campuses of the London Health Sciences Centre, London, Ontario, Canada. All isolates were speciated using conventional biochemical tests and cellular fatty acid profiles determined by gas-liquid chromatography. 6 The presence or absence of the mecA gene was determined using multiplex PCR. 3 Thirteen species were represented amongst the isolates: Staphylococcus auricularis (five), Staphylococcus capitis 
Results
A summary of data is presented in Table 1 . Two hundred and eleven of 658 isolates tested (32%) were mecA positive. Interestingly, 221/447 mecA-negative isolates had an oxacillin MIC of >0.5 mg/L. Therefore, these were phenotypically resistant to oxacillin, using the NCCLS breakpoints for oxacillin susceptibility and resistance for CNS. 8 Quinupristin/dalfopristin was more active than clindamycin, and only 15/658 (2.3%) isolates were resistant. S. capitis, S. epidermidis, S. lugdunensis, S. schleiferi, S. simulans and S. warneri were most susceptible, with MIC 90 s of 0.5 or 1 mg/L. Approximately 29% of S. cohnii isolates were resistant to quinupristin/dalfopristin. Susceptibility to clindamycin was associated with susceptibility to quinupristin/ dalfopristin; however, resistance to clindamycin did not indicate quinupristin/dalfopristin resistance. Of 522 isolates that were susceptible to clindamycin, 410 (78.5%) were susceptible and 102 (19.5%) were classified in the intermediate category (for a total of 98.0%) for quinupristin/ dalfopristin. On the other hand, 95.5% of 136 clindamycinresistant strains were susceptible to quinupristin/dalfopristin.
Linezolid demonstrated good activity against all CNS and resistance to it was not observed. S. caprae was most susceptible with an MIC 90 of 1 mg/L. S. capitis, S. hominis, S. lugdunensis, S. haemolyticus, S. simulans and S. warneri had MIC 90 s of 2 mg/L. All the remaining species had an MIC 90 of 4 mg/L. Resistance to oxacillin, clindamycin or any other agent did not affect susceptibility to linezolid.
The activity of telithromycin against CNS was similar to that of clindamycin. Susceptibility and resistance to clindamycin were predictive of telithromycin MICs of <2 or >4 g/L.
Of 522 clindamycin-susceptible isolates, 98.1% had MICs of <2 g/L, and of 136 clindamycin-resistant strains, 123 (90.4%) had MICs of telithromycin > 4 g/L. Overall, activity of telithromycin against CNS was better than that of erythromycin, with resistance rates of 34.6% for erythromycin and 20.2% for telithromycin.
Discussion
The CNS are a heterogeneous group of organisms made up of approximately 15 species known to cause infections in man. They are important causes of infection, particularly in the presence of foreign bodies. Most clinical laboratories do not routinely speciate the CNS, and not all species are equally represented in infections. More than 90% of blood culture isolates belong to three species, S. epidermidis, S. haemolyticus and S. hominis. 2 The activity of oxacillin against different species of CNS is quite variable, as demonstrated previously. 3 Marked increases in multidrug-resistant Gram-positive bacteria have compromised the selection of agents available for therapy. 4 Emergence of vancomycin-resistant enterococci raised the concern that this resistance could be transferred to staphylococci, and recently a vancomycin-resistant S. aureus was isolated from a patient with a catheter exit-site infection. 9 New classes of antibiotics with novel mechanisms of action are highly desirable. Quinupristin/dalfopristin, linezolid, and to certain extent telithromycin, are such antibiotics.
Quinupristin/dalfopristin had good activity against most species of CNS regardless of the presence of the mecA gene. More than 97% of isolates had MICs of <4 g/L. Amongst the three most commonly occurring species, S. epidermidis, S. haemolyticus and S. hominis, resistance rates were <1.0%. Overall susceptibility results of this study are similar to those published previously. [10] [11] [12] However, species-specific rates of resistance in the present study differed significantly from those reported from Taiwan. 10 Susceptibility to clindamycin was found to be predictive of susceptibility to quinupristin/dalfopristin; a similar correlation has been reported for S. aureus. 13 Quinupristin/ dalfopristin, unlike other macrolides and lincosamides, is bactericidal and has a prolonged post-antibiotic effect, so that the potential for development of resistance is low. 14 Its use is complicated by a number of drug incompatibilities and its metabolism by the P450 cytochromes leads to numerous drug interactions. Resistance to quinupristin/dalfopristin has already been reported, both in E. faecium and staphylococci. Several mechanisms of resistance have been identified. 15 Linezolid, along with vancomycin, was the most active agent against the CNS isolates, both mecA positive and negative. A report from Taiwan documented non-susceptibility to linezolid in 2% of CNS isolates from that country. 10 Although clinical data are lacking, linezolid may prove to be a useful agent in treating CNS infections owing to its excellent oral bioavailability. There have been reports of reversible myelosuppression with longer-term use of linezolid, and further experience is needed on the use of this agent in infections requiring long-term therapy (such as prosthetic valve endocarditis or orthopaedic device infections). 16 In our study, telithromycin showed superior activity against mecA-positive and -negative CNS when compared with erythromycin. This observation has also been reported previously. [17] [18] [19] Activity was, however, no better than that of clindamycin. In the present study, susceptibility and resistance to clindamycin were predictive of susceptibility and resistance to telithromycin. A similar correlation was noted by Jamijian et al. 20 between clindamycin and another ketolide (RU-64004). 
